Setting: Klerksdorp-Tshepong Hospital Complex MDR-TB Unit, North-West Province, South Africa.
Introduction
Multi-drug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are both diseases of global concern. Multi-drug-resistant tuberculosis is defined as resistance to at least both isoniazid and rifampicin, while XDR-TB is defined as resistance to any fluoroquinolone and to at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in addition to multidrug resistance. 1 According to the World Health Organization (WHO), it is estimated that there were 480 000 new MDR-TB cases and 190 000 deaths globally in 2014. 2 Drugresistant TB (DR-TB) is associated with poor TB treatment outcomes; only 52% of MDR-TB patients and 22% of XDR-TB patients were reported cured in the 2013 cohort. 3 In managing DR-TB, sputum culture conversion from positive to negative is critical in identifying the patient's response to treatment. Sputum culture conversion is defined as two consecutive negative cultures from sputum samples obtained at least 30 days apart. Earlier sputum culture conversion during DR-TB treatment is associated with more favourable TB treatment outcomes. 4, 5 Differences have been observed between countries with regard to the time to sputum culture http://www.sajid.co.za Open Access conversion (TTSCC) as well as the factors that predict TTSCC. Given the high burden of DR-TB in South Africa, it is important to determine the TTSCC and to understand the factors predictive of the TTSCC among DR-TB patients in South Africa.
According to the WHO Global Tuberculosis Report 2014, South Africa is ranked among the top 10 countries with the highest burden of DR-TB. When looking at the final treatment outcomes, South Africa has poor results. In 2010, only 72% of 7386 diagnosed DR-TB cases were started on treatment, and of these, only 15% were cured, 40% died before completing treatment and 36% were lost to follow up. 6 In view of the fact that there are variations within and between provinces (geographical regions) in South Africa when it comes to the prevalence of DR-TB and treatment outcome, 7, 8 it is likely that there are differences between provinces in TTSCC and its predictors. It is important that we understand the TTSCC for different provinces to engage with the TB control programmes to tailor relevant interventions for different contexts.
The objective of this study was to determine the TTSCC and factors predictive of TTSCC in patients with MDR-TB and XDR-TB in the North-West Province, one of nine provinces in South Africa.
Study population and methods

Study design and setting
This was a retrospective cohort study, where we abstracted clinical and demographic data from medical records of MDR-TB and XDR-TB patients who were 18 years and older and were started on MDR-TB or XDR-TB treatment from 01 January 2012 to 31 
Data collection
Patients who were 18 years and older and were started on MDR-TB and XDR-TB treatment at the Klerksdorp-Tshepong MDR-TB Unit, from January 2012 to December 2014, were eligible for the study. A list of all eligible patients was obtained from the MDR-TB register on site. Medical records for all patients who met inclusion criteria were obtained and reviewed and a structured data extraction tool was used to abstract data. Explanatory variables were patient demographics, clinical characteristics and diagnostic data, TB management data, 1 sputum conversion data and treatment outcomes data. The outcome variable was TTSCC, defined as the duration, in days, between DR-TB treatment initiation and the date of collection of the first sputum culture specimen that was culture negative after a prior positive culture. Data abstracted to calculate TTSCC were the date of admission (a proxy for date of MDR/XDR-TB treatment initiation) and date of the first sputum that became negative after a previous positive result. Data were captured in Redcap software version 6.17.0. 9 Approval to conduct this study was obtained from the University of the Witwatersrand Human Research Ethics Committee (Medical), authorisation number: M150639, and permission to conduct the study was obtained from the Klerksdorp-Tshepong Hospital Complex. 
Data analysis
Ethical consideration
Ethical Clearance was issued on 26 June 2015 by the University of Witwatersrand Human Research Ethics Committee (Medical), number M150639.
Results
A total of 573 patients were enrolled in the study. The median age was 38 years (IQR 31-47), similar between MDR-TB and XDR-TB patients (p = 0.943). There were statistically significant differences between MDR-TB and XDR-TB patients for employment (43% vs 70%, p < 0.001). However, there were no differences between MDR-TB and XDR-TB patients -with formal education (89% vs 82%, p = 0.188), or their smoking history (26% vs 21%, p = 0.475), using alcohol (26% vs 35%, p = 0.249) or having an occupational history in gold mining (8% vs 13%, p = 0.234) ( Table 1 ). The median body mass index (BMI) was 18.1 (IQR: 16.2-21.2) and was similar between MDR-TB and XDR-TB patients (p = 0.521).
Of the 565 participants tested for HIV, 448 (79%) were
HIV-infected and of those with an available baseline CD4 count results on admission (430/448), 402 (93%) had a CD4 count < 500 cells/mm 3 . Of the 448 who were HIV-positive, 257 (58%) were on antiretroviral therapy (ART) on admission to hospital. There were no significant differences between MDR-TB and XDR-TB patients for their median haemoglobin ( , p = 0.820), as seen in Table 2 .
Among those enrolled, 355 (62%) had a GeneXpert MTB/ RIF (GXP) result prior to initiation of therapy of whom 352 (99%) were positive for Mycobacterium tuberculosis with Table 3 ).
The final analysis of the TTSCC used data from 371 patients with a positive sputum culture result on admission. Of these, 329 (89%) were MDR-TB patients, while 42 (11%) were XDR-TB patients (Figure 1 ).
The overall median TTSCC for both the MDR-TB and XDR-TB patients was 58.2 days (IQR 29-113); and 56 days (IQR 28-99) and 139 days (IQR 54-245) for MDR-TB and XDR-TB patients, respectively (Figure 2) . A total of 262/374 (70%) achieved sputum culture conversion. Of these, 230 (69%) were MDR-TB patients and 32 (76%) were XDR-TB patients. Of the patients who achieved sputum culture conversion, 16 (50%) XDR-TB patients were treated using 8-10 drugs and 13 (41%) of the XDR-TB patients converted between 61 and 180 days, while 196 (75%) of MDR-TB patients were treated using three to five drugs and 138 (53%) converted in less than 60 days. Of the 230 MDR-TB patients who achieved sputum culture conversion, 111 (48%) achieved treatment success and 35 (15%) died; while among the 32 XDR-TB patients, 13 (41%) achieved treatment success and 3 (9%) died ( Table 4 ).
In the univariate analysis model, being underweight (HR: 0.68, 95% CI: 0.49-0.94, p = 0.023), Acid Fast Bacilli (AFB) positivity on admission (HR: 0.71, 95% CI: 0.56-0.88, p = 0.002) and having XDR-TB (HR: 0.51, 95% CI: 0.36-0.73, p < 0.001) were associated with longer TTSCC ( Table 5 ).
In the multivariable analysis that included a priori variables, being underweight (HR: 0.63, 95% CI: 0.45-0.88, p = 0.008), having XDR-TB (HR: 0.36, 95% CI: 0.19-0.69, p = 0.002) and older age (HR: 0.98, 95% CI: 0.96-0.99, p = 0.024) were associated with longer TTSCC. AFB positivity on sputum on admission was marginally significant and was associated with longer TTSCC (HR: 0.72, 95% CI: 0.51-1.01, p = 0.059) ( Table 5 ).
Discussion
Early sputum culture conversion is predictive of favourable TB treatment outcomes. 10 This study reports the TTSCC and its predictors among MDR-TB and XDR-TB patients treated at Klerksdorp-Tshepong Hospital in South Africa. We found the median TTSCC for MDR-TB and XDR-TB patients to be 56 days (IQR 28-99) and 139 days (IQR 54-245), respectively. Being underweight, AFB positivity on admission and being diagnosed with XDR-TB were associated with longer TTSCC. Our study was not able to demonstrate predictors of shorter TTSCC.
Our findings regarding TTSCC were similar to those found in a KwaZulu-Natal study which reported a median TTSCC of 62 days (IQR: 48-111) for MDR-TB patients; 11 but different from studies in three other provinces in South Africa (Cape Town, North West and Gauteng) which reported significantly longer (> 270 days) TTSCC for XDR-TB patients. 12 These results are in keeping with what was found in Peru, where the XDR-TB patients obtained culture conversion later than MDR-TB patients. 13 Evidence has shown that several factors influence both shorter and longer TTSCC. Factors that influence longer sputum conversion include the drug-resistance pattern on drug susceptibility testing (DST), a high baseline sputum bacilli count, patients with cavities on the chest X-ray and patients with a previous history of susceptible TB or MDR-TB with a negative outcome such as treatment failure or relapse, while factors associated with shorter conversion include being HIV co-infected. 14, 15, 16, 17, 18, 19 In our study, patients who were underweight achieved longer TTSCC than those with a normal weight and this was also found in the literature. 20 In our study, most patients were underweight on admission. Compared to those with normal weight, MDR-TB patients who are underweight are likely to present with clinical characteristics identified as predictors of longer TTSCC, including severe disease, cavities on the X-ray and a high sputum bacilli count. 16, 17, 21, 22 In the literature, the causal relationship between being underweight and DR-TB has not been proven but we do know that DR-TB can lead to wasting, increased risk of DR-TB and death. 20, 23 Underweight patients have macro-and micronutrient deficiencies which impair immune response to infections. 24 Although the causal relationship between weight gain and shorter TTSCC has not been proven, studies have shown that being underweight can lead to unfavourable treatment outcomes such as treatment failure and death. Patients who are underweight have reduced bioavailability and malabsorption of anti-TB drugs and this can contribute to longer TTSCC and subsequently treatment failure. 21, 24 A randomised control trial in India showed that adding nutritional supplementation can lead to a higher sputum conversion rate. 25 Therefore, patients with DR-TB who are older and underweight should be assessed for hypoalbuminemia and micronutrient deficiencies. Nutritional supplements should be provided as studies support shorter TTSCC. 23, 25, 26, 27 Our findings have shown that patients with XDR-TB are likely to take longer to achieve sputum culture conversion compared to MDR-TB patients. Extensively drug-resistant TB is resistant to the most potent anti-TB drugs (rifampicin and isoniazid) as well as second-line drugs and injectables and fluoroquinolones and this makes the treatment of XDR-TB a challenge. The combination therapy for XDR-TB consists of less potent, highly toxic anti-TB drugs which are given over a longer period and this contributes to longer TTSCC. 28 During our study, new drugs such as bedaquiline and delaminid were undergoing trials which have shown that the use of bedaquiline can shorten the TTSCC in treatment of DR-TB. 29 Therefore, the inclusion of such drugs in the management of patients with MDR-TB and XDR-TB can lead to shorter TTSCC.
Our study confirmed that AFB positivity on the smear confirmed findings from previous studies. 17, 20, 30 High bacilli count on admission demonstrates the high burden of resistant bacilli in the lung. Second-line drugs that are used to treat DR-TB are less efficacious, the bacilli will take longer to respond to the treatment and this leads to longer TTSCC. 7 Our study demonstrated that increased age correlates with longer TTSCC. Patients develop more co-morbid diseases and have reduced immune responses and more drug-drug interactions as they age. These factors may also increase TTSCC. 31 The study has several limitations. Retrospective record reviews are limited by missing or incomplete data, and for our study, we had missing data such as the specific date of treatment initiation; therefore, we used the data of admission as a proxy for date of treatment initiation. There were missing follow-up sputum culture results as well and this influenced the number of censored patients in the survival analysis as well as the confirmation of cured patients. The impact of missing data was also evident with regard to HIV tests, CD4 count and Antiretroviral (ARV) treatment. The denominator for the CD4 count is different from the total number of HIV-positive patients and the denominator for patients on ARVs on admission is different from the number of patients who are HIV-positive and had a CD4 count.
Conclusion
The time to sputum culture conversion has both clinical and public health significance in managing DR-TB. Longer TTSCC is an indicator for poor DR-TB treatment outcomes, such as treatment failure, relapse and death. Our study has shown that age, being underweight while on DR-TB treatment, AFB positivity on admission and having XDR-TB predict longer TTSCC. Although the causal relationship between weight gain and shorter TTSCC has not been proven, studies have shown that being underweight can lead to unfavourable treatment outcomes such as death. Patients with AFB positivity should be monitored closely and their treatment optimised as they are infectious and are likely to spread the disease further.
